Nxera Pharma, Jan-Mar (1Q) Net Income Loss Narrows

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri May 2, 2025 3:30 pm JST Earnings

4565 Nxera Pharma Co., Ltd. 【IFRS】

Earnings Report

Nxera Pharma Co., Ltd. <4565> [TSE Prime] announced its financial results (based on IFRS) after the market closed on May 2nd (15:30). The consolidated net loss for the first quarter of the fiscal year ending December 2025 (January to March) was a reduced loss of 0.76 billion yen (compared to a loss of 3.28 billion yen in the same period last year).

In the most recent three-month period, from January to March (1Q), the operating profit/loss margin drastically improved from -66.7% in the same period last year to -33.0%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Mar, 2023	943	-1,964	-1,863	-1,402	-17.1	ー	May 12, 2023	IFRS
Jan - Mar, 2024	4,611	-3,076	-2,796	-3,281	-36.7	ー	May 9, 2024	IFRS
Jan - Mar, 2025	6,644	-2,193	-2,156	-760	-8.5	ー	May 2, 2025	IFRS
YoY	+44.1%	+28.7%	+22.9%	+76.8%	+77.0%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2024	12,720	-3,654	-3,158	-4,703	-52.5	0	Aug 9, 2024	IFRS
Jan - Jun, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 14, 2025	IFRS
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	12,766	-9,526	-10,680	-7,193	-87.2	0	Feb 13, 2024	IFRS
Dec, 2024	28,835	-5,423	-4,662	-4,838	-53.9	0	Feb 14, 2025	IFRS
Dec, 2025 Guidance	ー	ー	ー	ー	－	0	Feb 14, 2025	IFRS
YoY	－	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	4,611	-3,076	-2,796	-3,281	-36.7	-66.7	May 9, 2024	IFRS
Apr - Jun, 2024	8,109	-578	-362	-1,422	-15.9	-7.1	Aug 9, 2024	IFRS
Jul - Sep, 2024	9,263	808	865	1,200	13.4	8.7	Nov 1, 2024	IFRS
Oct - Dec, 2024	6,852	-2,577	-2,369	-1,335	-14.9	-37.6	Feb 14, 2025	IFRS
Jan - Mar, 2025	6,644	-2,193	-2,156	-760	-8.5	-33.0	May 2, 2025	IFRS
YoY	+44.1%	+28.7%	+22.9%	+76.8%	+77.0%